Literature DB >> 22358876

Reinforcing apoptosis-resistance of COS and myeloma cells by transfecting with bcl-2 gene.

T Fujita, S Terada, K Fukuoka, A Kitayama, H Ueda, E Suzuki.   

Abstract

COS, myeloma and HeLa cells, which are commonly used for protein production by cell culture, were transfected with human bcl-2 gene encoded on the shuttle vector BCMGS. Expression of human bcl-2 improved survival of cells remarkably, mildly, or negligibly for COS, myeloma, and HeLa, respectively. Four clones were obtained from the human bcl-2 expressing cell population of COS cells. They expressed human bcl-2 almost at the same level. The viable cell numbers were 6, 2.5, 2.5, and 0.8 times as many for the clones #8, #5, #6, and #7, respectively, as for the control COS cells, when they were cultured at low (0.2%) serum concentration for 9 days. The bcl-2 overexpressing COS cells showed morphology different from that of the control COS cells in serum limited condition. When transfected with mouse lambda protein gene carried by an SV40-derived vector, clone #8 of the bcl-2 transfected COS cells continued the transient expression of lambda protein longer than the control COS cells.

Entities:  

Year:  1997        PMID: 22358876      PMCID: PMC3466756          DOI: 10.1023/A:1007935026770

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  17 in total

1.  Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death.

Authors:  S Henderson; M Rowe; C Gregory; D Croom-Carter; F Wang; R Longnecker; E Kieff; A Rickinson
Journal:  Cell       Date:  1991-06-28       Impact factor: 41.582

2.  Overexpression of bcl-2, apoptosis suppressing gene: Prolonged viable culture period of hybridoma and enhanced antibody production.

Authors:  Y Itoh; H Ueda; E Suzuki
Journal:  Biotechnol Bioeng       Date:  1995-10-20       Impact factor: 4.530

3.  Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell.

Authors:  Y Tsujimoto
Journal:  Oncogene       Date:  1989-11       Impact factor: 9.867

Review 4.  Cell death (apoptosis) in cell culture systems.

Authors:  T G Cotter; M al-Rubeai
Journal:  Trends Biotechnol       Date:  1995-04       Impact factor: 19.536

Review 5.  Molecular regulation of apoptosis: genetic controls on cell death.

Authors:  G T Williams; C A Smith
Journal:  Cell       Date:  1993-09-10       Impact factor: 41.582

6.  Overexpression of the human BCL-2 gene product results in growth enhancement of Epstein-Barr virus-immortalized B cells.

Authors:  Y Tsujimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

7.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.

Authors:  D L Vaux; S Cory; J M Adams
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

8.  NSO myeloma cell death: Influence of bcl-2 overexpression.

Authors:  K Murray; C E Ang; K Gull; J A Hickman; A J Dickson
Journal:  Biotechnol Bioeng       Date:  1996-08-05       Impact factor: 4.530

9.  Involvement of the bcl-2 gene in human follicular lymphoma.

Authors:  Y Tsujimoto; J Cossman; E Jaffe; C M Croce
Journal:  Science       Date:  1985-06-21       Impact factor: 47.728

10.  The proteins encoded by the VpreB and lambda 5 pre-B cell-specific genes can associate with each other and with mu heavy chain.

Authors:  H Karasuyama; A Kudo; F Melchers
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  2 in total

1.  Protection of hybridoma cells against apoptosis by a loop domain-deficient Bcl-xL protein.

Authors:  J Charbonneau; E Gauthier
Journal:  Cytotechnology       Date:  2001-09       Impact factor: 2.058

2.  Prolongation of murine hybridoma cell survival in stationary batch culture by Bcl-xL expression.

Authors:  J R Charbonneau; E R Gauthier
Journal:  Cytotechnology       Date:  2000-10       Impact factor: 2.058

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.